Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group

Viscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dos...

Descripción completa

Detalles Bibliográficos
Autores: Conrozier, Thierry, Raman, Raghu, Chevalier, Xavier, Henrotin, Yves, Monfort Faure, Jorge, Diraçoglù, Demirhan, Bard, Hervé, Baron, Dominique, Jerosch, Jörg, Richette, Pascal, Migliore, Alberto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/53631
Acceso en línea:http://hdl.handle.net/10230/53631
http://dx.doi.org/10.1177/1759720X211018605
Access Level:acceso abierto
Palabra clave:EUROVISCO
Hip
Hyaluronic acid
Intra-articular injection
Knee
Osteoarthritis
Recommendations
Viscosupplementation
id ES_a7e3f61ba01eb81ddbf1114f33a0fe40
oai_identifier_str oai:repositori.upf.edu:10230/53631
network_acronym_str ES
network_name_str España
repository_id_str
spelling Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO groupConrozier, ThierryRaman, RaghuChevalier, XavierHenrotin, YvesMonfort Faure, JorgeDiraçoglù, DemirhanBard, HervéBaron, DominiqueJerosch, JörgRichette, PascalMigliore, AlbertoEUROVISCOHipHyaluronic acidIntra-articular injectionKneeOsteoarthritisRecommendationsViscosupplementationViscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dosing regimen and the modalities of retreatment. A multidisciplinary committee of European experts on OA (EUROVISCO) was constituted to formulate recommendations, aimed at helping physicians in the decision-making and the optimal achievement of VS. Before each session members were tasked to collate an exhaustive literature review. Level of evidence and strength of recommendation were based on the level of agreement for each item according to the Delphi method. In 2015, a consensus position was proposed for 24 statements. Among those that obtained a consensual agreement, the working group stressed that VS is effective in mild/moderate knee OA but is not an alternative to surgery in advanced OA, and that dosing regimen must be supported by controlled trials. In 2018, two decision algorithms for the retreatment with IA-HA in knee OA were published. Among the key recommendations, the experts recommended to re-treat every year patients with high risk of OA progression, even if not symptomatic. In 2020, EUROVISCO published two sets of recommendations for the design of clinical trials on the disease-modifying effect of VS and for optimizing the results of VS. The working group underlined that an accurate analysis of radiological features and symptoms and a careful clinical examination may improve the chances of success of VS, as well as good technique of injection and the use of imaging guidance. Based on the exhaustive analysis of the literature and their own clinical experience, the EUROVISCO experts offer a wide range of recommendations intended to help practitioners, particularly in certain cases where the specific characteristics of the patients make the therapeutic decision difficult.SAGE Publications202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/53631http://dx.doi.org/10.1177/1759720X211018605reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésTher Adv Musculoskelet Dis. 2021 May 28;13:1759720X211018605© The Author(s), 2021. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/536312026-06-12T07:21:37Z
dc.title.none.fl_str_mv Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
title Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
spellingShingle Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
Conrozier, Thierry
EUROVISCO
Hip
Hyaluronic acid
Intra-articular injection
Knee
Osteoarthritis
Recommendations
Viscosupplementation
title_short Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
title_full Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
title_fullStr Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
title_full_unstemmed Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
title_sort Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group
dc.creator.none.fl_str_mv Conrozier, Thierry
Raman, Raghu
Chevalier, Xavier
Henrotin, Yves
Monfort Faure, Jorge
Diraçoglù, Demirhan
Bard, Hervé
Baron, Dominique
Jerosch, Jörg
Richette, Pascal
Migliore, Alberto
author Conrozier, Thierry
author_facet Conrozier, Thierry
Raman, Raghu
Chevalier, Xavier
Henrotin, Yves
Monfort Faure, Jorge
Diraçoglù, Demirhan
Bard, Hervé
Baron, Dominique
Jerosch, Jörg
Richette, Pascal
Migliore, Alberto
author_role author
author2 Raman, Raghu
Chevalier, Xavier
Henrotin, Yves
Monfort Faure, Jorge
Diraçoglù, Demirhan
Bard, Hervé
Baron, Dominique
Jerosch, Jörg
Richette, Pascal
Migliore, Alberto
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv EUROVISCO
Hip
Hyaluronic acid
Intra-articular injection
Knee
Osteoarthritis
Recommendations
Viscosupplementation
topic EUROVISCO
Hip
Hyaluronic acid
Intra-articular injection
Knee
Osteoarthritis
Recommendations
Viscosupplementation
description Viscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dosing regimen and the modalities of retreatment. A multidisciplinary committee of European experts on OA (EUROVISCO) was constituted to formulate recommendations, aimed at helping physicians in the decision-making and the optimal achievement of VS. Before each session members were tasked to collate an exhaustive literature review. Level of evidence and strength of recommendation were based on the level of agreement for each item according to the Delphi method. In 2015, a consensus position was proposed for 24 statements. Among those that obtained a consensual agreement, the working group stressed that VS is effective in mild/moderate knee OA but is not an alternative to surgery in advanced OA, and that dosing regimen must be supported by controlled trials. In 2018, two decision algorithms for the retreatment with IA-HA in knee OA were published. Among the key recommendations, the experts recommended to re-treat every year patients with high risk of OA progression, even if not symptomatic. In 2020, EUROVISCO published two sets of recommendations for the design of clinical trials on the disease-modifying effect of VS and for optimizing the results of VS. The working group underlined that an accurate analysis of radiological features and symptoms and a careful clinical examination may improve the chances of success of VS, as well as good technique of injection and the use of imaging guidance. Based on the exhaustive analysis of the literature and their own clinical experience, the EUROVISCO experts offer a wide range of recommendations intended to help practitioners, particularly in certain cases where the specific characteristics of the patients make the therapeutic decision difficult.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/53631
http://dx.doi.org/10.1177/1759720X211018605
url http://hdl.handle.net/10230/53631
http://dx.doi.org/10.1177/1759720X211018605
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Ther Adv Musculoskelet Dis. 2021 May 28;13:1759720X211018605
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415815735934976
score 15.81155

Similares en LA Referencia